<doc>
  <docmeta id="113hr1367ih">
    <bill congress="113" type="hr" number="1367" version="ih"/>
    <revision size="26644" annotations="0" id="11" commit-time="2013-04-12T16:36:09+00:00" committer="favila" doc="113hr1367ih/11.xml" status="complete">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HF7F0A3062EF94BD9A647F5ACF8013999" public-private="public">
	<metadata>
<dublinCore>
<title>113 HR 1367 IH: FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act</title>
<publisher>U.S. House of Representatives</publisher>
<date>2013-03-21</date>
<format>text/xml</format>
<language>EN</language>
<rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 1367</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130321">March 21, 2013</action-date>
			<action-desc>
        <sponsor name-id="L000562">Mr. Lynch</sponsor> (for
			 himself, <cosponsor name-id="C000984">Mr. Cummings</cosponsor>,
			 <cosponsor name-id="M000933">Mr. Moran</cosponsor>, and
			 <cosponsor name-id="N000147">Ms. Norton</cosponsor>) introduced the following
			 bill; which was referred to the <committee-name committee-id="HGO00">Committee
			 on Oversight and Government Reform</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/5/89">chapter 89</external-xref> of title 5, United States Code, to
		  ensure program integrity, transparency, and cost savings in the pricing and
		  contracting of prescription drug benefits under the Federal Employees Health
		  Benefits Program.</official-title>
	</form>
	<legis-body id="H142C37E153924DFDAADD0E61E3B3FE0B" style="OLC">
		<section id="H745E35806EF2432EAAC5128452598D7E" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the
			 <quote>
          <short-title>FEHBP Prescription Drug Integrity,
			 Transparency, and Cost Savings Act</short-title>
        </quote>.</text>
		</section>
    <section id="H2CA5CE445E814F4D95CAF28D41C499D0">
      <enum>2.</enum>
      <header>Improved program
			 integrity, transparency, and cost savings for prescription drug benefits in the
			 Federal Employees Health Benefits Program</header>
			<subsection id="HBE4A77C43B654E7F81675AFB079B95F2">
        <enum>(a)</enum>
        <header>Change in
			 contracting requirements</header>
        <text display-inline="yes-display-inline">
          <external-xref legal-doc="usc" parsable-cite="usc/5/8902">Section 8902</external-xref> of title 5, United States
			 Code, is amended by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="H7C625E8856594DC7975D15074CFE712A" style="USC">
					<subsection id="H4574BAF02B1A4A4A8A25AE2FA4BC4571">
            <enum>(p)</enum>
            <text display-inline="yes-display-inline">A contract may not be made or a plan
				approved under this chapter, with respect to a carrier that is a party to a PBM
				carrier arrangement, unless the PBM and such carrier comply with the
				requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/8915">section 8915</cato:entity-ref>. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office</cato:entity-ref> shall terminate such contract or
				discontinue such plan for failure to comply with such
				requirements.</text>
					</subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="H42DE404977A04F89A7B970757B9A9C61">
        <enum>(b)</enum>
        <header>Requirements for
			 PBMs and related requirements for carriers</header>
        <text display-inline="yes-display-inline">
          <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/5/89">Chapter 89</external-xref> of title 5, United States Code,
			 is amended by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="H95E5B4BEF88E471394A195BEC03950F0" style="USC">
					<section id="H86D0505CED1E41178D74DA52F39B9F75">
            <enum>8915.</enum>
            <header>Requirements
				for PBM arrangements</header>
						<subsection display-inline="no-display-inline" id="HF5BE3F9693FF4B6A81098657D5550396">
              <enum>(a)</enum>
              <header>Limitations on
				Cross-Ownership</header>
							<paragraph id="H320DA24179524303B78238E6321CFDE9">
                <enum>(1)</enum>
                <header>In
				general</header>
                <text display-inline="yes-display-inline">Under a PBM carrier
				arrangement a PBM may not be under common corporate control with—</text>
								<subparagraph id="H0487E8BB9C15468BAB99092D30D7512B">
                  <enum>(A)</enum>
                  <text>a prescription
				drug manufacturer; or</text>
								</subparagraph>
                <subparagraph id="H31F4AD04C97A44FFBCD680268C109823">
                  <enum>(B)</enum>
                  <text>a retail
				pharmacy.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" id="HCBC8A891021D41FD8CE6214E014FDD23">
                <enum>(2)</enum>
                <header>Profit
				restriction on corporately affiliated carriers and PBMs</header>
                <text display-inline="yes-display-inline">With respect to a PBM carrier arrangement
				related to a contract under this chapter, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office</cato:entity-ref> may not permit a carrier
				under common corporate control with a PBM to earn a profit resulting from such
				control.</text>
							</paragraph>
              <paragraph id="HE9B75EAEC8E14B1DB69A0FC25A6A1E68">
                <enum>(3)</enum>
                <header>Certification</header>
                <text display-inline="yes-display-inline">Each carrier shall certify annually to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office of Personnel Management</cato:entity-ref> that any PBM with which it has a PBM carrier
				arrangement meets the requirements of this subsection.</text>
							</paragraph>
              <paragraph id="H221CD8189A6D499A9E8FBD7BC580E09E">
                <enum>(4)</enum>
                <header>Definitions</header>
                <text>For
				purposes of this subsection—</text>
								<subparagraph id="HA3279AAD3ACB4346ACFEEEA5122775A2">
                  <enum>(A)</enum>
                  <header>Common corporate
				control</header>
                  <text>The term <term>common corporate control</term> means that
				2 entities are part of a controlled group of corporations (as such term is
				defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Internal Revenue Code of 1986/s:1563">
                      <external-xref legal-doc="usc" parsable-cite="usc/26/1563">section 1563</external-xref> of the Internal Revenue Code of 1986</cato:entity-ref>).</text>
								</subparagraph>
                <subparagraph id="H8639CC1D50554CB9A57265ECF11781B7">
                  <enum>(B)</enum>
                  <header>Retail
				pharmacy</header>
                  <text display-inline="yes-display-inline">The term
				<term>retail pharmacy</term> excludes any mail order pharmacy.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="HCB4592283D4C48E28404A8BAC392EB99">
              <enum>(b)</enum>
              <header>Restrictions on
				brand name prescription drug substitutions</header>
							<paragraph id="H2D957250B85344D9AC7F6D9583075DF0">
                <enum>(1)</enum>
                <header>In
				general</header>
                <text>Under a PBM carrier arrangement, and with respect to a
				prescription drug prescribed to an enrollee covered under such arrangement, a
				PBM may not request payment from a carrier for a brand name prescription drug
				that was dispensed to the enrollee, at the request of the PBM, in substitution
				for the drug that was originally prescribed to such enrollee, unless each of
				the following requirements is met:</text>
								<subparagraph id="H2BFD51BCAC1A40CDB56377A363BC1E2F">
                  <enum>(A)</enum>
                  <header>Lower net
				cost</header>
                  <text>The substitute drug has a lower net cost than the drug
				originally prescribed to such enrollee.</text>
								</subparagraph>
                <subparagraph id="H25A6960265A74647AACDD72B31023878">
                  <enum>(B)</enum>
                  <header>Authorization by
				prescriber</header>
                  <text>The prescriber of the originally prescribed drug
				submits an express, verifiable authorization of the substitution to the
				pharmacist and such authorization includes a determination by the prescriber
				that the drug substitution will not endanger the health of the enrollee for
				whom the drug is prescribed.</text>
								</subparagraph>
                <subparagraph id="H6A4D66BD3D7D4CF39035F0D9A8FB1006">
                  <enum>(C)</enum>
                  <header>Additional
				requirements</header>
                  <text>Each of the requirements described in
				<internal-xref idref="HE7964D253D3342F9BA0638E3C3E9002E" legis-path="8915.(b)(2)">
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/8915/b/2" proposed="true">paragraph (2)</cato:entity-ref>
                    </internal-xref> are met.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HE7964D253D3342F9BA0638E3C3E9002E">
                <enum>(2)</enum>
                <header>Additional
				requirements</header>
                <text display-inline="yes-display-inline">The requirements
				described in this paragraph are, with respect to a brand name prescription drug
				that was dispensed to an enrollee, at the request of the PBM, in substitution
				for the drug that was originally prescribed to such enrollee, the
				following:</text>
								<subparagraph commented="no" id="H891DD0BABBFD44C5B8E5563D6D5AE379">
                  <enum>(A)</enum>
                  <text>To the extent
				appropriate, the PBM consults the enrollee concerning such drug
				substitution.</text>
								</subparagraph>
                <subparagraph commented="no" id="HD1F03C2B1F5D4E52A2147DBA29206FD9">
                  <enum>(B)</enum>
                  <text>The PBM discloses
				to the prescriber of the originally prescribed drug, the carrier, and the
				enrollee for whom such drug was prescribed—</text>
									<clause commented="no" id="H182E71382C7A44B7A5D474C90EC6FABA">
                    <enum>(i)</enum>
                    <text>the reason why the
				PBM proposed a drug substitution for such drug; and</text>
									</clause>
                  <clause commented="no" id="H95DD11346F8B4E258A719DDD18266FA6">
                    <enum>(ii)</enum>
                    <text>the financial
				impact of the drug substitution on the PBM, the carrier, and the
				enrollee.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" id="H1F318166429445FB973ABAFEFDEBCF3F">
                  <enum>(C)</enum>
                  <text>In the case of a
				mail order pharmacy, the PBM ensures that, at the time the drug is dispensed,
				the enrollee receives a written notice that such drug substitution occurred and
				that such substitution occurred with the approval of the prescriber.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HFAEEED6E91954A0F921A4E6BF4B44AF9">
                <enum>(3)</enum>
                <header>Definitions</header>
                <text>For
				purposes of this subsection—</text>
								<subparagraph id="H76589652E8B746A59445692771148104">
                  <enum>(A)</enum>
                  <header>Brand name
				prescription drug</header>
                  <text display-inline="yes-display-inline">The term
				<term>brand name prescription drug</term> means a drug approved pursuant to an
				application submitted under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                      <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b">section 505(b) of the Federal Food, Drug, and
				Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355">
                        <cato:entity-ref entity-type="uscode" value="usc/21/355/b">21 U.S.C. 355(b)</cato:entity-ref>
                      </external-xref>)</cato:entity>.</text>
								</subparagraph>
                <subparagraph id="H11D2254AC1A448CFAC596B84350EB6CE">
                  <enum>(B)</enum>
                  <header>Net
				cost</header>
                  <text>The term <term>net cost</term> means, with respect to a
				drug, a carrier, and an enrollee, the sum of—</text>
									<clause id="H3F29638FE515415FB18D42E84E412A83">
                    <enum>(i)</enum>
                    <text>the final cost of
				the drug to the carrier after all adjustments (including discounts, rebates,
				associated dispensing fees and administrative fees, and enrollee cost sharing);
				and</text>
									</clause>
                  <clause id="H5F9B96D899674283BD19A557A8BAC989">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">the final cost of the drug to the enrollee
				(including cost-sharing).</text>
									</clause>
                </subparagraph>
                <subparagraph display-inline="no-display-inline" id="H489158ED37FE4037AC50CA519083496F">
                  <enum>(C)</enum>
                  <header>Prescriber</header>
                  <text>The
				term <term>prescriber</term> means an individual who is authorized under State
				and Federal law to prescribe drugs and who prescribes a drug to an enrollee of
				a health benefits plan under this chapter.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection display-inline="no-display-inline" id="H628730DDF71F4BD2B312548E962C1B06">
              <enum>(c)</enum>
              <header>Reimbursement of
				carriers</header>
              <text display-inline="yes-display-inline">Under a PBM carrier
				arrangement, not later than the last day of each quarter of the contract
				year—</text>
							<paragraph id="H2507F4C07DFE4BC2A4874352BF96748E">
                <enum>(1)</enum>
                <text>the PBM shall pay
				to a carrier an amount that is at least 99 percent of the sum of—</text>
								<subparagraph id="H97FCBB9820F949188B03E21DBCF0E856">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">all compensation that the PBM received
				during the previous quarter from a prescription drug manufacturer under a PBM
				manufacturer contract (to the extent such arrangement relates to the PBM
				carrier arrangement) including compensation (but excluding rebates) that the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office of Personnel Management</cato:entity-ref> categorizes (regardless of how such compensation
				is categorized by the PBM) as—</text>
									<clause id="H937D631F7DEC4D719BD6470B6F77E988">
                    <enum>(i)</enum>
                    <text>market share
				incentives;</text>
									</clause>
                  <clause id="HE47A23A37B504222A7BB4CDAB8438D3F">
                    <enum>(ii)</enum>
                    <text>prescription drug
				substitution programs;</text>
									</clause>
                  <clause id="HB86C39BD682F4F6CA809506D674ABA85">
                    <enum>(iii)</enum>
                    <text>educational
				support;</text>
									</clause>
                  <clause id="HFB46FF8A206748CD8EEB65ABD1694729">
                    <enum>(iv)</enum>
                    <text>commissions;</text>
									</clause>
                  <clause id="H89E7F86190FB4235BCA5C8D191046DF6">
                    <enum>(v)</enum>
                    <text>mail service
				purchase discounts;</text>
									</clause>
                  <clause id="H1AA6F6B14EE74622A18456DDA44B05B3">
                    <enum>(vi)</enum>
                    <text>administrative or
				management fees; or</text>
									</clause>
                  <clause id="H5345681B23DE4D139A0998D141C25A71">
                    <enum>(vii)</enum>
                    <text>any other form
				of compensation;</text>
									</clause>
                </subparagraph>
                <subparagraph id="HCEEF11E28DE54468B012DB7DF7B86687">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">all compensation received by the PBM during
				the previous quarter for sales of utilization or claims data that the PBM
				possesses as a result of the PBM carrier arrangement; and</text>
								</subparagraph>
                <subparagraph id="H93EF87C7109C4F44A280818DC89322DA">
                  <enum>(C)</enum>
                  <text display-inline="yes-display-inline">all rebates paid to the PBM during the
				previous quarter by a prescription drug manufacturer to the extent that such
				rebates are based on prescription drugs dispensed under the PBM carrier
				arrangement; and</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HC1F5CA425A5E46DE948076013E1496F3">
                <enum>(2)</enum>
                <text display-inline="yes-display-inline">the PBM shall disclose to the carrier and
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office</cato:entity-ref>, in a form and manner specified by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office</cato:entity-ref>—</text>
								<subparagraph id="HD62C89EB59CA4398B8B46AD8DEF26A6F">
                  <enum>(A)</enum>
                  <text>the compensation
				described in
				<internal-xref idref="H97FCBB9820F949188B03E21DBCF0E856" legis-path="8915.(c)(1)(A)">
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/8915/c/1/A" proposed="true">paragraph (1)(A)</cato:entity-ref>
                    </internal-xref>, by the amount of
				compensation for each category under such paragraph;</text>
								</subparagraph>
                <subparagraph id="H5D84281F22BA4AF9AC0486FFFC862003">
                  <enum>(B)</enum>
                  <text>the compensation
				described in
				<internal-xref idref="HCEEF11E28DE54468B012DB7DF7B86687" legis-path="8915.(c)(1)(B)">
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/8915/c/1/B" proposed="true">paragraph (1)(B)</cato:entity-ref>
                    </internal-xref>; and</text>
								</subparagraph>
                <subparagraph id="H442ACF55544F4463A9A1A56452F964B3">
                  <enum>(C)</enum>
                  <text>the rebates
				described in
				<internal-xref idref="H93EF87C7109C4F44A280818DC89322DA" legis-path="8915.(c)(1)(C)">
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/8915/c/1/C" proposed="true">paragraph (1)(C)</cato:entity-ref>
                    </internal-xref>, on a drug-by-drug
				basis.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="HACDA067F246144EF930BE18CC2E4FCA2">
              <enum>(d)</enum>
              <header>Sale of
				utilization and claims data</header>
              <text display-inline="yes-display-inline">Under a PBM carrier arrangement, if the PBM
				intends to sell utilization or claims data that the PBM possesses as a result
				of such arrangement—</text>
							<paragraph id="HBC7964D27D354E24B944F8949214FB19">
                <enum>(1)</enum>
                <text display-inline="yes-display-inline">the PBM shall notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office of
				Personnel Management</cato:entity-ref> before selling such data and shall provide the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office</cato:entity-ref> with
				the name of the potential purchaser of such data and the expected use of such
				data by such purchaser; and</text>
							</paragraph>
              <paragraph id="HCF3DD060C5DD42C29A2541476E3D96AD">
                <enum>(2)</enum>
                <text>the PBM may not
				sell such data unless the sale complies with all Federal and State laws and the
				PBM has received approval for such sale from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office</cato:entity-ref>.</text>
							</paragraph>
            </subsection>
            <subsection id="H427837BE502B4DBFAE3961C8C2A17236">
              <enum>(e)</enum>
              <header>Pricing</header>
							<paragraph id="H8346CB9512DC4133B1C4B9BE3E8FC1BA">
                <enum>(1)</enum>
                <header>Spread
				pricing</header>
								<subparagraph id="H6566FF38E6CB47F1BF6E157CEA6E2DBE">
                  <enum>(A)</enum>
                  <header>Limitation on
				charges to a carrier</header>
                  <text>A PBM under a PBM carrier arrangement shall
				not charge a carrier an amount for a prescription drug that is covered under
				such arrangement (and is dispensed by a pharmacy) that is more than the amount
				(including the ingredient cost and the dispensing fee) that the PBM reimburses
				the pharmacy for the drug.</text>
								</subparagraph>
                <subparagraph id="H3238A52404D2468F8819483F6B96E0CB">
                  <enum>(B)</enum>
                  <header>Disclosures</header>
									<clause id="H93A056EF7C2B4719A30E6DEE0D09F8D7">
                    <enum>(i)</enum>
                    <header>Initial
				disclosure</header>
                    <text>Before entering into a PBM carrier arrangement, the
				PBM shall disclose to the carrier and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office of Personnel Management</cato:entity-ref> the
				reimbursement basis (including the type of benchmark price and the source of
				the data for determining such price) and methodology that the PBM uses to
				compute reimbursement amounts for retail and mail order pharmacies.</text>
									</clause>
                  <clause id="HD5CFCF95D4404938A1C69D4B9550E02C">
                    <enum>(ii)</enum>
                    <header>Updates</header>
                    <text display-inline="yes-display-inline">Not later than 30 days after making a
				change to the reimbursement basis or methodology under
				<internal-xref idref="H93A056EF7C2B4719A30E6DEE0D09F8D7" legis-path="8915.(e)(1)(B)(i)">
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/8915/e/1/B/i" proposed="true">clause (i)</cato:entity-ref>
                      </internal-xref>, the PBM shall
				disclose such change to the carrier and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office</cato:entity-ref>.</text>
									</clause>
                  <clause id="HDC15D6A41D824B6B973F427903E8DB96">
                    <enum>(iii)</enum>
                    <header>Transition
				rule</header>
                    <text display-inline="yes-display-inline">In the case of a PBM
				carrier arrangement that is in effect on the effective date of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act" proposed="true">FEHBP
				Prescription Drug Integrity, Transparency, and Cost Savings Act</cato:entity-ref>, the PBM shall
				disclose the information under
				<internal-xref idref="H93A056EF7C2B4719A30E6DEE0D09F8D7" legis-path="8915.(e)(1)(B)(i)">
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/8915/e/1/B/i" proposed="true">clause (i)</cato:entity-ref>
                      </internal-xref> not later than 1 year
				after such date.</text>
									</clause>
                </subparagraph>
              </paragraph>
              <paragraph id="H248819A6E94848C9A7E684DB00E2B74C">
                <enum>(2)</enum>
                <header>Maximum for mail
				order prescription drugs prices and dispensing fees</header>
								<subparagraph id="HE8F4521D5FCF46F285B62A88FD84FFD3">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>If a prescription drug is supplied by a mail order
				pharmacy to an enrollee, under a PBM carrier arrangement, a PBM may not charge
				a carrier an amount for the ingredient cost for such prescription drug that is
				greater than an amount that is equal to the actual acquisition cost for the
				drug minus any cost sharing for such drug that is the responsibility of the
				enrollee.</text>
								</subparagraph>
                <subparagraph id="H68F7B9813CE84988ADA921440767A763">
                  <enum>(B)</enum>
                  <header>Dispensing
				fee</header>
                  <text display-inline="yes-display-inline">Under a PBM carrier
				arrangement, a PBM may not charge a carrier an amount for a dispensing fee
				related to a prescription drug dispensed by a mail order pharmacy to an
				enrollee that is greater than the amount that the PBM charges health plans for
				similar services that are not covered under a PBM carrier arrangement.</text>
								</subparagraph>
                <subparagraph id="H209D82D9D41844C3A203639048FF65A3">
                  <enum>(C)</enum>
                  <header>Transparency</header>
                  <text>Under
				a PBM carrier arrangement, a PBM shall provide the carrier and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office of
				Personnel Management</cato:entity-ref>, at the request of such carrier or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office</cato:entity-ref>, information on
				the method used to determine the amount of—</text>
									<clause id="H5CB9A90FC4D6411D971A295957F98692">
                    <enum>(i)</enum>
                    <text>the ingredient
				cost under
				<internal-xref idref="HE8F4521D5FCF46F285B62A88FD84FFD3" legis-path="8915.(e)(2)(A)">
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/8915/e/2/A" proposed="true">subparagraph (A)</cato:entity-ref>; </internal-xref> and</text>
									</clause>
                  <clause id="H20F4E4CA1A7A4F208110650B5D5744E6">
                    <enum>(ii)</enum>
                    <text>the dispensing
				fee under
				<internal-xref idref="H68F7B9813CE84988ADA921440767A763" legis-path="8915.(e)(2)(B)">
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/8915/e/2/B" proposed="true">subparagraph (B)</cato:entity-ref>
                      </internal-xref>.</text>
									</clause>
                </subparagraph>
                <subparagraph display-inline="no-display-inline" id="H680C5CBBF6DD41F98B3FEA37664D6C2C">
                  <enum>(D)</enum>
                  <header>Actual
				acquisition cost defined</header>
                  <text>For purposes of this paragraph, the term
				<term>actual acquisition cost</term> means the amount a pharmacy pays for a
				prescription drug, net of discounts, rebates, charge backs, and other
				adjustments to the price of the drug.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="H2FC4352219674D8991F62D83F5F9B930">
              <enum>(f)</enum>
              <header>Right to
				explanation of benefits</header>
              <text>Under a PBM carrier arrangement, not
				later than 90 days after the date on which a pharmacy dispenses a prescription
				drug covered under the arrangement, the PBM shall provide (by mail or
				electronically) to the enrollee to whom such drug was dispensed an explanation
				of benefits statement that contains the following information:</text>
							<paragraph id="HEF1D61039F694058B9E2DC12118229A8">
                <enum>(1)</enum>
                <text>The date the claim
				for such drug was made by the pharmacy.</text>
							</paragraph>
              <paragraph id="HB8C604329FCF4E0DABF1576847BC33B4">
                <enum>(2)</enum>
                <text>The name of such
				drug and the strength and quantity dispensed to the enrollee.</text>
							</paragraph>
              <paragraph id="H642BCF689DCD480180DE6CD793CF3B47">
                <enum>(3)</enum>
                <text>The amount paid by
				the enrollee for such drug.</text>
							</paragraph>
              <paragraph id="H3BC69DFAA85242D08A04352317E697C4">
                <enum>(4)</enum>
                <text display-inline="yes-display-inline">The total amount paid to the pharmacy by
				the PBM for such drug. Such amount shall include all amounts paid to the
				pharmacy with respect to dispensing such drug, including fees.</text>
							</paragraph>
              <paragraph id="HC3E3C4D2A8C04278AE8D0AA49FD90C12">
                <enum>(5)</enum>
                <text>The amount paid by
				the carrier to the PBM for such drug.</text>
							</paragraph>
            </subsection>
            <subsection id="HFA56B195B37B487A87247A54102A6505">
              <enum>(g)</enum>
              <header>Nondiscriminatory
				contract</header>
							<paragraph id="H376A76292EE3405CB982B0647EBA1CD1">
                <enum>(1)</enum>
                <header>In
				general</header>
                <text>Under a PBM carrier arrangement, a PBM may not require
				that a pharmacy participate in a pharmacy network managed by such PBM as a
				condition of the pharmacy participating in another network managed by such
				PBM.</text>
							</paragraph>
              <paragraph id="H1D59C87D28A94D938E997389128BED71">
                <enum>(2)</enum>
                <header>Pharmacy network
				defined</header>
                <text>For purposes of this subsection, the term <term>pharmacy
				network</term> means a group of pharmacies that have agreed, through a contract
				with a PBM or carrier, to provide prescription medications to enrollees at
				rates and with discounts that are specified in such contract.</text>
							</paragraph>
            </subsection>
            <subsection id="H90C7FBA06D8747F38311B22B9410AD86">
              <enum>(h)</enum>
              <header>Access to PBM
				contract information</header>
							<paragraph id="H5F96E632A34941398AAC07CF17A4196C">
                <enum>(1)</enum>
                <header>In
				general</header>
                <text>Under a PBM carrier arrangement, at the request of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office of Personnel Management</cato:entity-ref>, a PBM shall provide to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office</cato:entity-ref> and to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Inspector General" entity-parent-id="2400">Inspector General of the Office of Personnel Management</cato:entity-ref> full access to
				information relating to contracts entered into by such PBM under such
				arrangement (such as PBM manufacturer contracts and PBM contracts with
				pharmacies). Such information shall include—</text>
								<subparagraph id="H2454BE38C9A24C4A96DAD5E0ADC3C2F2">
                  <enum>(A)</enum>
                  <text>companywide rebate
				receipt aging reports that cover all of the PBM’s lines of business;</text>
								</subparagraph>
                <subparagraph id="H34EF69E48FFA4FDA9718E31EF752B538">
                  <enum>(B)</enum>
                  <text>information and
				methodology used to calculate and allocate rebates between the PBM’s lines of
				business;</text>
								</subparagraph>
                <subparagraph id="H763EA735660443E192795CBBDC10717B">
                  <enum>(C)</enum>
                  <text>information on
				average wholesale prices, wholesale acquisition costs, and maximum allowable
				costs;</text>
								</subparagraph>
                <subparagraph id="H9815EB7FF40A41059E83264ACE38BFE3">
                  <enum>(D)</enum>
                  <text>information on
				dispensing fees paid; and</text>
								</subparagraph>
                <subparagraph id="H730FF616BA044C68B4C7752CD7225AEF">
                  <enum>(E)</enum>
                  <text>information and
				methodologies used to calculate additional administrative and service fees
				charged to the carrier.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H46D1E5389813403F9556BF1DD3076F7C">
                <enum>(2)</enum>
                <header>Confidentiality</header>
                <text display-inline="yes-display-inline">Information provided by a PBM under this
				subsection is confidential and shall not be disclosed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office</cato:entity-ref>, except
				that nothing in this paragraph shall prevent—</text>
								<subparagraph id="H383BB92CF307498D97F6FA7699A087A3">
                  <enum>(A)</enum>
                  <text>a disclosure
				required under the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Inspector General Act of 1978">Inspector General Act of 1978</cato:entity-ref>; or</text>
								</subparagraph>
                <subparagraph id="H89D3C1C3E5D049F8B2D5FB86D03FE3CF">
                  <enum>(B)</enum>
                  <text>any disclosure
				which the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office</cato:entity-ref>, in its sole discretion, considers necessary in order to carry
				out this section, if such disclosure is made in a form which does not disclose
				the identity of a specific PBM or carrier or the price charged for a particular
				prescription drug.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H1224062303B9448F8942520583DAE63A">
                <enum>(3)</enum>
                <header>Exemption from
				FOIA</header>
                <text>Any information obtained under this subsection shall be
				exempt from disclosure under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/552">section 552</cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="H196CD3942B0D418A86D6BE77E586C484">
                <enum>(4)</enum>
                <header>Definitions</header>
                <text>For
				purposes of this subsection—</text>
								<subparagraph display-inline="no-display-inline" id="H5EAFAF31CB914D128A7553066AAE4DE1">
                  <enum>(A)</enum>
                  <header>Generic
				drug</header>
                  <text display-inline="yes-display-inline">The term <term>generic
				drug</term> means a drug approved pursuant to an abbreviated application
				submitted under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                      <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j">section 505(j) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/355/j">21
				U.S.C. 355(j)</cato:entity-ref>)</cato:entity>.</text>
								</subparagraph>
                <subparagraph id="H6F5736075EA341768DB578BAFAE955F9">
                  <enum>(B)</enum>
                  <header>Maximum
				allowable cost</header>
                  <text>The term <term>maximum allowable cost</term> means
				a cost that is set by a PBM as the upper payment limit on the ingredient costs
				for a generic drug.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="H256C3600BC1B4A7CA7E914FD05871B81">
                  <enum>(C)</enum>
                  <header>Wholesale
				acquisition cost</header>
                  <text>The term <term>wholesale acquisition cost</term>
				means a publicly available list price for sales of a drug by a manufacturer to
				a wholesaler.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="H8BE287169B374111AA128BE8ED9ABF5D">
              <enum>(i)</enum>
              <header>Treatment of
				non-Compliance</header>
							<paragraph id="H79401824957447CAA522C0ECD1752C7F">
                <enum>(1)</enum>
                <header>In
				general</header>
                <text>Under a PBM carrier arrangement, a PBM that knowingly
				provides false information to a carrier related to a claim made to such carrier
				by the PBM under such arrangement shall be treated, for purposes of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc-chapter/31/37">chapter 37
				of title 31</cato:entity-ref>, in the same manner as a person that makes a false claim to the
				United States Government under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/31/3729">section 3729</cato:entity-ref> of such chapter.</text>
							</paragraph>
              <paragraph id="H2B5A56D988C74F08B8FE0994FFF47E6C">
                <enum>(2)</enum>
                <header>Use of
				collections</header>
                <text>Any monetary penalty collected under
				<internal-xref idref="H79401824957447CAA522C0ECD1752C7F" legis-path="8915.(i)(1)">
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/8915/i/1" proposed="true">paragraph (1)</cato:entity-ref>
                  </internal-xref> shall be deposited into
				the Employees Health Benefits Fund under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/8909">section 8909</cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="H985612185F894895AD3A18BE8BBBBF48">
                <enum>(3)</enum>
                <header>Additional
				penalties</header>
                <text>Any penalties resulting from the application of
				<internal-xref idref="H79401824957447CAA522C0ECD1752C7F" legis-path="8915.(i)(1)">
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/8915/i/1" proposed="true">paragraph (1)</cato:entity-ref>
                  </internal-xref> shall be in addition to
				any other penalties available to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office of Personnel Management</cato:entity-ref> under law
				or regulation.</text>
							</paragraph>
            </subsection>
            <subsection id="H70BAB18759FD43489AEB1CE6749D5AD5">
              <enum>(j)</enum>
              <header>No application
				to community-Rated carriers</header>
              <text display-inline="yes-display-inline">The provisions of this section and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/8902/p">section
				8902(p) of this title</cato:entity-ref>—</text>
							<paragraph id="H62E62020CFDA4471A070043336D3E5ED">
                <enum>(1)</enum>
                <text>shall apply to
				experience-rated carriers; and</text>
							</paragraph>
              <paragraph id="H2A4461180FC74E91BC63AA7FB58685E8">
                <enum>(2)</enum>
                <text>shall not apply to
				carriers that use rates based on a per member per month capitation
				amount.</text>
							</paragraph>
            </subsection>
            <subsection id="H8253D14A184E4C69BFCC8212294C1420">
              <enum>(k)</enum>
              <header>Limitation of
				application to prescription drugs</header>
              <text display-inline="yes-display-inline">The provisions of this section and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/8902/p">section
				8902(p)</cato:entity-ref> of this title shall not be construed to apply to drugs that are not
				prescription drugs.</text>
						</subsection>
            <subsection id="H892461B9B65C412AA15AA8B762675BBB">
              <enum>(l)</enum>
              <header>General
				definitions</header>
              <text>For purposes of this section and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/8902/p">section 8902(p) of
				this title</cato:entity-ref>:</text>
							<paragraph id="H63F00318A19443378C1B1788D90A384C">
                <enum>(1)</enum>
                <header>Dispensing
				fee</header>
                <text>The term <term>dispensing fee</term> means a fee paid to a
				pharmacy for the service of filling or dispensing prescriptions and excludes
				any payment for the cost of the drug dispensed.</text>
							</paragraph>
              <paragraph id="HCDB4686648F44809BAF97C1C676A4C66">
                <enum>(2)</enum>
                <header>Drug
				substitution</header>
                <text>The term <term>drug substitution</term> means any
				change from one prescription drug to another prescription drug that is intended
				to address or treat the same illness or condition.</text>
							</paragraph>
              <paragraph id="H7CACFC1E062B4BEC827FA35E2061C501">
                <enum>(3)</enum>
                <header>PBM carrier
				arrangement</header>
                <text>The term <term>PBM carrier arrangement</term> means a
				contract between a PBM and a carrier for the provision or administration of a
				program of prescription drug coverage under a health benefits plan under this
				chapter. Such a contract may provide, among other duties, for the PBM
				to—</text>
								<subparagraph id="H6AA015162D6745BA874624F282ED3162">
                  <enum>(A)</enum>
                  <text>process and pay
				prescription drug claims;</text>
								</subparagraph>
                <subparagraph id="HC6288EDFBC96448198E129CD0AF43E15">
                  <enum>(B)</enum>
                  <text>provide programs
				and services designed to—</text>
									<clause id="HC672F4DD24F5448FA16604F6FAB7AAD8">
                    <enum>(i)</enum>
                    <text>maximize the
				effectiveness of prescription drugs dispensed under such plan; or</text>
									</clause>
                  <clause id="H87A0F62324D04919AF926387014DB314">
                    <enum>(ii)</enum>
                    <text>contain
				prescription drug expenditures under such plan; and</text>
									</clause>
                </subparagraph>
                <subparagraph id="H620970AD6B764E638D08780901C42C91">
                  <enum>(C)</enum>
                  <text>engage in other
				activities related to the administration of such prescription drug
				coverage.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" id="HD9FF06B332904A279F3BD741BBB42552">
                <enum>(4)</enum>
                <header>PBM manufacturer
				contract</header>
                <text>The term <term>PBM manufacturer contract</term> means a
				contract between a PBM and a prescription drug manufacturer for the provision
				of prescription drugs to enrollees of health benefits plans with prescription
				drug coverage that is administered or provided by the PBM.</text>
							</paragraph>
              <paragraph id="HE9BAA40252464FD39756FAAF6F45B6AE">
                <enum>(5)</enum>
                <header>Pharmacy benefit
				manager; PBM</header>
                <text>The terms <term>pharmacy benefit manager</term> and
				<term>PBM</term> mean an entity that contracts with a carrier to provide or
				administer prescription drug coverage under a health benefits plan under this
				chapter.</text>
							</paragraph>
            </subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="H90F5ABC296D549FA941684F03D69B2BE">
        <enum>(c)</enum>
        <header>Clerical
			 amendment</header>
        <text>The table of sections for <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/5/89">chapter 89</external-xref> of title 5, United
			 States Code, is amended by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="H21CF365D620543FC8444FD3E71D63039" style="USC">
					<toc regeneration="no-regeneration">
						<toc-entry level="section">8915. Requirements for PBM
				arrangements.</toc-entry>
					</toc>
					<after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="HB0EDE905A4514841B5922634B8490715">
        <enum>(d)</enum>
        <header>Effective Date;
			 waiver; regulations</header>
				<paragraph id="H03AE2AB4B9F1434AA75AAF63D3094250">
          <enum>(1)</enum>
          <header>Effective
			 date</header>
          <text>The amendments made by this section shall apply to contract
			 years beginning on or after January 1, 2014.</text>
				</paragraph>
        <paragraph id="H01F444A0CA7743BDAE159B20D31FF969">
          <enum>(2)</enum>
          <header>Waiver</header>
          <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office of Personnel Management</cato:entity-ref> may
			 waive the application of 1 or more of the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/8915">section 8915 of title
			 5, United States Code</cato:entity-ref>, but only for contract year 2014.</text>
				</paragraph>
        <paragraph id="HB9F317F138D64247B6C17CD47D45FB05">
          <enum>(3)</enum>
          <header>Expediting
			 implementation of regulations</header>
          <text display-inline="yes-display-inline">Not later than 6 months after the date of
			 the enactment of this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office of Personnel Management</cato:entity-ref> shall issue
			 interim final regulations to carry out this section which may be effective and
			 final immediately on an interim basis as of the date of publication of such
			 regulations. If the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office</cato:entity-ref> provides for an interim final regulation, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office</cato:entity-ref>
			 shall provide for a period of public comment on such regulation after the date
			 of publication. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2400">Office</cato:entity-ref> may change or revise such regulation after
			 completion of the period of public comment.</text>
				</paragraph>
      </subsection>
    </section>
  </legis-body>
</bill>
</doc>